ArticlePloS one2026
Association between sexual dysfunction and symptom burden in women with Chronic Obstructive Pulmonary Disease.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate sexual dysfunction as a clinically relevant but under-recognized manifestation of disease burden in women with COPD and to identify its clinical and psychological determinants. STUDY
designIn this cross-sectional study, 100 consecutive women with stable COPD (mean age 57 ± 7 years) attending an outpatient chest clinic were enrolled.
main outcome measuresParticipants underwent pulmonary function testing and completed the COPD Assessment Test (CAT), Modified Medical Research Council (mMRC) scale, Beck Depression Inventory, Short Form-36 (SF-36), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-FS), and Female Sexual Function Index (FSFI).
resultsSexual dysfunction (FSFI ≤26.55) was more prevalent in patients with greater disease burden, particularly those in GOLD stage E, and was associated with significantly higher fatigue and depressive symptoms. FSFI scores showed a positive correlation with FACIT-FS and quality-of-life domains, and a negative correlation with depression scores (all p < 0.05). In multivariable analysis, fatigue was positively associated with FSFI scores, whereas depression and body mass index were negatively associated. Patients with more severe disease (GOLD E), comorbidities, and dyspnea during intercourse had lower FSFI scores, while those receiving triple therapy demonstrated higher scores.
conclusionsSexual dysfunction was associated with greater symptom burden in women with COPD and was closely related to fatigue and depression. Assessment of sexual function may contribute to a more comprehensive evaluation of disease burden in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.